The third national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from complicated urinary tract infection patients

Authors:

Abstract
No abstract available
Funding Information
  • Astellas Pharma Inc.
  • Chugai Pharmaceutical
  • Daiichi-Sankyo
  • Daito Pharmaceutical Co., Ltd.
  • FUJIFILM Pharma Co., Ltd.
  • GlaxoSmithKline
  • K. K., Kobayashi Kako Co., Ltd.
  • KYORIN Pharmaceutical Co., Ltd.
  • Maruho Co., Ltd.
  • Meiji Seika Pharma
  • MSD K.K., Nichi-Iko Pharmaceutical Co., Ltd.
  • Nihon Pharmaceutical Co., Ltd.
  • Nipro Corporation
  • OHARA Pharmaceutical Co., Ltd.
  • Pfizer Japan
  • Sawai Pharmaceutical Co., Ltd.
  • Shionogi
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Taiho Pharmaceutical
  • Taisho Pharmaceutical Co., Ltd.
  • Takata Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Tatsumi Kagaku Co., Ltd.
  • Towa Pharmaceutical Co., Ltd.
  • Toyama Chemical Co., Ltd.
  • Yoshindo Inc

This publication has 12 references indexed in Scilit: